Table 1. Characteristics of the patients with high-grade serous adenocarcinoma (n=142).
| Clinicopathological variables | HtrA2-negative expression (n=36) (%) | HtrA2-positive expression (n=106) (%) | P-value |
|---|---|---|---|
|
Age (years) | |||
| <55 | 20 (56) | 57 (54) | 0.85 |
| ⩾55 |
16 (44) |
49 (46) |
|
|
ECOG PS | |||
| 0 | 33 (92) | 102 (96) | 0.37 |
| 1/2 |
3 (8) |
4 (4) |
|
|
FIGO stage | |||
| I | 4 (11) | 12 (11) | 0.70 |
| II | 4 (11) | 7 (7) | |
| III | 21 (58) | 58 (55) | |
| IV |
7 (20) |
29 (27) |
|
|
Residual tumour | |||
| None | 9 (25) | 19 (18) | 0.48 |
| <1 cm | 4 (11) | 19 (18) | |
| >1 cm |
23 (64) |
68 (64) |
|
|
Adjuvant chemotherapy | |||
| Conventional platinum-based chemotherapy | 34 (94) | 42 (40) | <0.01 |
| Taxane+platinum | 2 (6) | 64 (60) | |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; FIGO=The International Federation of Gynecology and Obstetrics; PS=performance status.